EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Improved health‐related quality of life during peptide receptor radionuclide therapy in patients with neuroendocrine tumours

Katarina Edfeldt iD, Per Hellman, Dan Granberg, Pernilla Lagergren, Espen Thiis-Evensen iD, Anders Sundin iD, Camilla Andersson

Journal of Neuroendocrinology · 2023

DOI: 10.1111/jne.13342 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuroendocrinology, 2023. Verfasst von Katarina Edfeldt und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuroendocrine tumours (NETs) can arise in different locations in the body, and may give rise to hormonal symptoms, which amongst other factors may affect patients' health‐related quality of life (HRQoL). Up to four cycles of peptide receptor radionuclide therapy (PRRT) have been shown effective for symptom alleviation and prolonging progression‐free survival. The aim of this study was to assess the patient's perspective regarding changes in their HRQoL during PRRT. HRQoL was assessed using the questionnaires for cancer in general, EORTC QLQ‐C30, and the gastrointestinal NET‐specifically EORTC QLQ‐GINET21. Patients with NET ( n = 204) rated their HRQoL before PRRT cycles one and four. The medical records of patients were reviewed and their HRQoL was compared to a matched reference population ( n = 4910). HRQoL was found to improve during PRRT in aspects of global quality of life; role, social, and emotional functioning, and multiple symptom relief. Potential risk groups for worse HRQoL during PRRT were patients with overweight (BMI >25) who completed four cycles of PRRT and older patients (>65 years old). In conclusion, we found that PRRT improves HRQoL in patients with NETs. The results of this study may be used to improve person‐centred care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsPancreatic NeoplasmsHumansAgedQuality of LifeRadioisotopesReceptors, Peptide

Stichwörter der Autor:innen

HRQoLNETPRRTquality of life

Substanzen

RadioisotopesReceptors, Peptide

Autor:innen und Institutionen

  • Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
  • Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
  • Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway.

ORCID-Profile: Katarina Edfeldt, Espen Thiis-Evensen, Anders Sundin

Zitieren

APA

Edfeldt, K., Hellman, P., Granberg, D., Lagergren, P., Thiis-Evensen, E., Sundin, A., & Andersson, C. (2023). Improved health‐related quality of life during peptide receptor radionuclide therapy in patients with neuroendocrine tumours. Journal of Neuroendocrinology. https://doi.org/10.1111/jne.13342

Vancouver

Edfeldt K, Hellman P, Granberg D, Lagergren P, Thiis-Evensen E, Sundin A, et al. Improved health‐related quality of life during peptide receptor radionuclide therapy in patients with neuroendocrine tumours. Journal of Neuroendocrinology. 2023. doi:10.1111/jne.13342

BibTeX
@article{Edfeldt2023,
  author = {Edfeldt, Katarina and Hellman, Per and Granberg, Dan and Lagergren, Pernilla and Thiis-Evensen, Espen and Sundin, Anders and Andersson, Camilla},
  title = {Improved health‐related quality of life during peptide receptor radionuclide therapy in patients with neuroendocrine tumours},
  journal = {Journal of Neuroendocrinology},
  year = {2023},
  doi = {10.1111/jne.13342}
}
Kostenlos starten →